[1] Marty Wulferink, et al. The Peptide hLF1-11 as Broad Spectrum Antmicrobial Prophylaxis in HSCT Patients. Blood (2005) 106 (11): 3241.
[2] van der Does AM, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2010 Feb;54(2):811-6. DOI:
10.1128/AAC.00652-09[3] van der Does AM, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol. 2012 May 15;188(10):5012-9. DOI:
10.4049/jimmunol.1102777[4] Faber C, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother. 2005 Jun;49(6):2438-44. DOI:
10.1128/AAC.49.6.2438-2444.2005[5] Lupetti A, et al. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother. 2000 Dec;44(12):3257-63. DOI:
10.1128/AAC.44.12.3257-3263.2000[6] upetti A, et al. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007 Nov 1;196(9):1416-24. DOI:
10.1086/522427